Assessing Risk of Adverse Pregnancy Outcomes for Immuno-Oncology Programs
The "Assessing Risk of Adverse Pregnancy Outcomes for Immuno-Oncology Programs" is 1 of 10 courses included in the Cancer Immunotherapies module.
This course is led by Dr. Curtis Maier Director at Glaxo Smith Kline
- Understand the role of the immune system in successful pregnancy
- Appreciate that many of the pathways targeted in IO are also involved in maintaining pregnancy, particularly immune tolerance of fetal antigens
- Knowledge of regulatory guidance and different scientifically justified approaches for assessing reproductive toxicology risk with IO agents